帕博利珠单抗联合放疗和手术对比单纯放疗和手术治疗III期肢体软组织肉瘤的安全性与疗效(SU2C-SARC032):一项开放标签随机临床试验
这项开放标签随机临床试验在20家学术机构纳入143例III期肢体未分化多形性肉瘤或去分化/多形性脂肪肉瘤患者,随机分为术前放疗后手术(对照组)或术前帕博利珠单抗联合放疗后手术及术后帕博利珠单抗(试验组)。改良意向治疗分析127例、中位随访43个月显示,试验组无病生存期显著优于对照组(HR 0.61,90%CI 0.39-0.96,单侧p=0.035),2年无病生存率对照组52%、试验组67%;试验组≥3级不良事件发生率56%,高于对照组的31%。
要点
- 在意向治疗人群中,加用帕博利珠单抗同样改善无病生存期(HR 0.61,90%CI 0.39-0.95)。
- 试验组2年无病生存率67%,对照组52%,加用帕博利珠单抗提高15%。
- 试验组≥3级不良事件发生率56%,高于对照组的31%。
核心结论
- 在术前放疗和手术基础上加用帕博利珠单抗可改善III期肢体未分化多形性肉瘤及多形性或去分化脂肪肉瘤患者的无病生存期,为这些患者建立了一种有前景的新治疗选择。
研究设计与样本
- 开放标签随机临床试验,在澳大利亚、加拿大、意大利和美国的20家学术机构入组grade 2或3、III期肢体及肢带区未分化多形性肉瘤或去分化/多形性脂肪肉瘤患者。
- 2017年11月18日至2023年11月14日共143例参与者随机分配至术前放疗后手术(对照组)或术前帕博利珠单抗联合放疗(首剂帕博利珠单抗后1-14天开始放疗)后手术及术后帕博利珠单抗(试验组)。
- 帕博利珠单抗200 mg静脉注射每3周一次,术前3个周期(放疗前、放疗期间和放疗后),术后辅助周期不超过14个。
- 主要终点为无病生存期;试验注册号ClinicalTrials.gov NCT03092323。
主要发现
- 改良意向治疗分析127例、中位随访43个月,试验组(n=64)无病生存期显著长于对照组(n=63;单侧log-rank p=0.035;HR 0.61,90%CI 0.39-0.96)。
- 2年无病生存率对照组为52%(90%CI 42-64),试验组为67%(90%CI 58-78),加用帕博利珠单抗提高15%。
- 意向治疗人群无病生存期同样改善(HR 0.61,90%CI 0.39-0.95)。
- ≥3级不良事件试验组发生率为56%,对照组为31%,试验组更常见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately half of patients with localised, high-risk soft tissue sarcoma of the extremity develop metastases. We aimed to assess whether the addition of pembrolizumab to preoperative radiotherapy and surgery would improve disease-free survival. METHODS: We completed an open-label, randomised clinical trial in patients with grade 2 or 3, stage III undifferentiated pleomorphic sarcoma or dedifferentiated or pleomorphic liposarcoma of the extremity and limb girdle. Patients were enrolled at 20 academic institutions in Australia, Canada, Italy, and the USA. Patients were randomly assigned to preoperative radiotherapy then surgery (control group) or preoperative pembrolizumab with radiotherapy (initiated 1-14 days after the first dose of pembrolizumab) then surgery and postoperative pembrolizumab (experimental group). Pembrolizumab (200 mg intravenously every 3 weeks) was administered as three neoadjuvant cycles (before, during, and after radiotherapy) and 14 or less adjuvant cycles. Primary endpoint was disease-free survival. This study is registered with ClincialTrials.gov (NCT03092323). FINDINGS: Between Nov 18, 2017, and Nov 14, 2023, 143 participants were randomly assigned to treatment. A modified intention-to-treat analysis of 127 patients with median follow-up of 43 months showed that the experimental group (n=64) had significantly longer disease-free survival than the control group (n=63; log-rank one-sided p=0·035; hazard ratio [HR] 0·61; 90% CI 0·39-0·96). The 2-year disease-free survival increased by 15% with addition of pembrolizumab: 52% (90% CI 42-64) and 67% (90% CI 58-78) for the control and experimental groups, respectively. Disease-free survival was similarly improved with pembrolizumab for the intention-to-treat patient population (HR 0·61 [90% CI 0·39-0·95]). Grade 3 or higher adverse events occurred more frequently in the experimental group (56%) than the control group (31%). INTERPRETATION: Addition of pembrolizumab to preoperative radiotherapy and surgery improves disease-free survival for patients with stage III undifferentiated pleomorphic sarcoma and pleomorphic or dedifferentiated liposarcoma of the extremity, which establishes a promising new treatment option for these patients. FUNDING: Stand Up to Cancer and Merck Sharp & Dohme.
引用
- Mowery YM, Ballman KV, Hong AM, et al. Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial. Lancet. 2024. PMID: 39547252. doi:10.1016/S0140-6736(24)01812-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。